Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
Filed with Euronext · · 3 pages · English
Story so far
- Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
- Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
- Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Earlier from Transgene
- Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
- Transgene to Participate in Investor Access
- Transgene participera à l’Investor Access
- Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
- Mise à disposition du Rapport Financier Semestriel au 30 juin 2026
Later from Transgene
- First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent's BT-001 in Patients with Rectal Cancer
- Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
Follow Transgene into a list and get an email when it puts out news.
Follow Transgene